Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. Tumor growth in female progeny.

Published bySimone Steffensen Modified over 4 years ago

Similar presentations

Presentation on theme: "Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. Tumor growth in female progeny."— Presentation transcript:

1 Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. For prenatal/maternal BSp treatment (left), female C3(1)/SV40 or Her2/neu transgenic mice were administered either regular control diet or 26% BSp from the first day of conception until weaning. For postnatal early-life BSp group (middle), treatment started from 4 weeks of age until termination of the experiment. For postnatal adult treatment (right), treatment started from 8 weeks of age until termination of the experiment. A and B, Tumor incidence in SV40 (A) and Her2/neu (B) transgenic mice. C and D, Medium tumor latency; E and F, Tumor growth volume. *, P < 0.05; **, P < 0.01; ***, P < 0.001, significantly different from the control group. Yuanyuan Li et al. Cancer Prev Res 2018;11: ©2018 by American Association for Cancer Research

Download ppt "Tumor growth in female progeny with prenatal/maternal, postnatal early-life, and postnatal adult BSp dietary administrations. Tumor growth in female progeny."

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.

Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.
ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.

ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.
Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Effect of MI-773 and/or cisplatin in a preclinical model of ACC
Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.

Expression changes of specific epigenetic-controlled tumor-related genes by the prenatal/maternal BSp treatment. qRT-PCR and Western blot analysis were.
Schematic representation of experimental design for BSp dietary treatments. Schematic representation of experimental design for BSp dietary treatments.

Schematic representation of experimental design for BSp dietary treatments. Schematic representation of experimental design for BSp dietary treatments.
Effect of MI-773 dosing on long-term efficacy.

Effect of MI-773 dosing on long-term efficacy.
Gene expression of epigenetic modulators, HDAC1 and Dnmt1, and the histone acetylation modification patterns by the prenatal/maternal BSp dietary treatment.

Gene expression of epigenetic modulators, HDAC1 and Dnmt1, and the histone acetylation modification patterns by the prenatal/maternal BSp dietary treatment.
TFAP2A knockdown inhibits tumor growth in vivo.

TFAP2A knockdown inhibits tumor growth in vivo.
Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.
Experimental schema. Experimental schema. Female C3 (1)/SV40 Tag mice were weaned from their mothers at 3 wk of age; behavior was assessed using a standard.

Experimental schema. Experimental schema. Female C3 (1)/SV40 Tag mice were weaned from their mothers at 3 wk of age; behavior was assessed using a standard.
Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.

Effects of AG on the colon histology score in the acute DSS colitis model. Effects of AG on the colon histology score in the acute DSS colitis model. Ten.
NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP-28122 orally, 100 mg/kg,

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,
Socially isolated SV40 Tag mice develop significantly larger mammary gland tumors. Socially isolated SV40 Tag mice develop significantly larger mammary.

Socially isolated SV40 Tag mice develop significantly larger mammary gland tumors. Socially isolated SV40 Tag mice develop significantly larger mammary.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.
The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.
Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.
In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

In vivo growth-inhibitory effect of perifosine on bevacizumab-resistant CCC. A, the effect of bevacizumab (BEV) on CCC growth in vivo. In vivo growth-inhibitory.

Similar presentations

Ads by Google